Therapy with an immune checkpoint inhibitor is associated with a number of adverse skin reactions.
Targets: CTLA4 (cytotoxic T lymphocyte-associated antigen 4) and PD-L1/PD-1 (programmed death-1)
Skin toxicities may include:
(1) alopecia areata
(2) xerosis cutis
(3) photosensitivity
(4) lichenoid skin reactions
(5) psorasiform skin reaction or exacerbation of psoriasis
(6) alterations in melanocytes (regression of nevi, vitiligo-like depigmentation)
(7) bullous pemphigoid
(8) acantholytic dyskeratosis
(9) maculopapular rash
(10) DRESS, Sweet syndrome, Stevens-Johnson syndrome or toxic epidermal necrolysis (TEN)
(11) pruritis
To read more or access our algorithms and calculators, please log in or register.
Specialty: Hematology Oncology, Dermatology
